GHRS NASDAQ
Credit Risk of going bust: lower than 88% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Total debt $360K against a stock market value of $1.32B.
Distance to default 12.47 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $180K (short-term plus half of long-term), stock volatility 69.7%; Altman Z'' 32.86. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Dublin, DU D02 RY95
IE
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Schonharting Florian | 0 | — | 2026-04-01 | |
| Moore Duncan | 0 | — | 2026-03-18 | |
| Cameron Aaron Luke | 33,211 | $21.32 | 2026-03-18 | |
| Cameron Aaron Luke | 25,000 | $5.80 | 2026-03-18 | |
| Hanley Dermot John | 0 | — | 2026-03-18 |